SCHEDULE: Select Medical Completes Acquisition by Consortium

Select Medical Holdings Corporation announced the completion of its acquisition by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe (WCAS) for $16.50 per share.

Summary

• Select Medical Holdings Corporation has been acquired by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe (WCAS).
• The acquisition was completed on June 30, 2026, with the transaction becoming effective on July 1, 2026.
• The purchase price was $16.50 per share, representing an 18% premium over the unaffected share price as of November 24, 2025, and a 25% premium over the 90-day volume-weighted average closing share price.
• The total valuation of the company is approximately $3.9 billion.
• Following the acquisition, Select Medical's common stock will cease trading on the New York Stock Exchange (NYSE) and will be delisted.
• The existing management team, including Mr. Ortenzio and Mr. Jackson, will continue to lead the company.
• The transaction was approved by Select Medical's stockholders at a Special Meeting on June 26, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for existing shareholders due to the significant premium offered, but neutral to slightly negative for public market investors due to the delisting and increased debt.

Positives

• The acquisition provides a significant premium for shareholders, with a $16.50 per share price representing an 18% premium over the unaffected share price and a 25% premium over the 90-day volume-weighted average.
• The deal was approved by Select Medical's stockholders, indicating broad support for the transaction.
• The continuity of the existing management team, including key figures like Robert A. Ortenzio and Martin F. Jackson, suggests a stable transition and continued operational expertise.
• The consortium, including a prominent private equity firm like WCAS, brings significant financial backing and strategic expertise.

Negatives

• Select Medical's common stock will be delisted from the NYSE, meaning it will no longer be publicly traded.
• The company's debt levels may increase significantly following the transaction, as indicated by the mention of committed debt financing.

Risks

• The integration of Select Medical into the new ownership structure could present operational challenges.
• The increased debt load may impact the company's financial flexibility and profitability in the future.
• The delisting from the NYSE will reduce liquidity for any remaining public shareholders and limit future access to public capital markets.

Future Outlook

With the acquisition complete and the company taken private, the future outlook will be shaped by the strategic direction set by the new ownership consortium, focusing on operational improvements and growth initiatives, likely with a significant debt structure.

Management Comments

• Select Medical Holdings Corporation today announced the completion of its acquisition by an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical, and Welsh, Carson, Anderson & Stowe (WCAS).
• Select Medical's current officers, including Mr. Ortenzio and Mr. Jackson, will continue to lead the business in their respective roles following the closing.
• Select Medical's stockholders, including the unaffiliated stockholders, voted to approve the transaction at our Special Meeting of Stockholders on June 26, 2026.

Industry Context

StockSavvy.ai notes that the acquisition of Select Medical by a private equity-backed consortium, including its own executive chairman and a senior executive, is a common trend in the healthcare services sector. This move to take a public company private often aims to allow for more flexible strategic and operational adjustments away from public market scrutiny, potentially leveraging debt financing to enhance returns.

Related Party Transactions

• Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, and Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical, are part of the consortium acquiring the company, indicating a related-party transaction.

Stakeholder Impact

• Shareholders: Receive $16.50 per share in cash, representing a significant premium, but will no longer have publicly traded stock.
• Employees: Current officers, including Mr. Ortenzio and Mr. Jackson, will continue in their roles, suggesting continuity for management.
• Creditors: The company's debt load is expected to increase due to the financing of the acquisition, potentially impacting future financial flexibility.

Next Steps

• Select Medical's common stock will cease trading on the NYSE.
• The company will be delisted from the New York Stock Exchange.
• The company will continue to be led by its current management team under new ownership.

Key Dates

Recommendation

The acquisition at a premium is positive for existing shareholders, but the delisting removes the opportunity for further upside or downside in the public market. For potential new investors, the company is now private, making direct investment difficult. Therefore, a 'hold' recommendation is appropriate for existing shareholders who have received the premium, while new investors would need to seek private investment opportunities.

Keywords

Select Medical Holdings Corporation, Acquisition, Merger, Robert A. Ortenzio, Martin F. Jackson, WCAS, Private Equity, Delisting, NYSE, Takeover